Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)
China · Delayed Price · Currency is CNY 8.18
-0.34 (-3.99%)
At close: Sep 11, 2026
SHE:301301 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 19,019 | 22,613 | 26,414 | 18,672 | 19,894 | - | |
Market Cap Growth | -25.71% | -14.39% | 41.47% | -6.14% | - | - |
Enterprise Value | 19,402 | 23,118 | 27,694 | 19,880 | 23,096 | - |
Last Close Price | 8.52 | 9.96 | 11.41 | 7.96 | 8.40 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 32.85 | 29.41 | 18.86 | 19.85 | 48.34 | - |
Forward PE | 20.78 | 22.87 | 16.86 | 20.74 | - | - |
PS Ratio | 4.36 | 4.90 | 4.59 | 3.87 | 5.21 | - |
PB Ratio | 2.38 | 2.79 | 3.34 | 2.68 | 3.20 | - |
P/TBV Ratio | 2.45 | 2.88 | 3.45 | 2.79 | 3.36 | - |
P/FCF Ratio | 22.91 | 50.05 | 15.11 | 19.71 | 30.87 | - |
P/OCF Ratio | 20.39 | 41.19 | 14.75 | 14.45 | 28.76 | - |
PEG Ratio | - | 0.56 | 0.56 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.44 | 5.01 | 4.81 | 4.12 | 6.05 | - |
EV/EBITDA Ratio | 14.46 | 15.00 | 12.16 | 11.49 | 18.98 | - |
EV/EBIT Ratio | 26.07 | 23.79 | 15.95 | 16.76 | 34.43 | - |
EV/FCF Ratio | 23.37 | 51.16 | 15.84 | 20.99 | 35.84 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.18 | 0.17 | 0.18 | 0.28 | 0.53 | 0.77 |
Debt / EBITDA Ratio | 1.05 | 0.89 | 0.62 | 1.12 | 2.68 | 3.99 |
Debt / FCF Ratio | 1.70 | 3.07 | 0.82 | 2.05 | 5.07 | 4.89 |
Net Debt / Equity Ratio | 0.05 | 0.08 | 0.04 | 0.17 | 0.26 | 0.66 |
Net Debt / EBITDA Ratio | 0.27 | 0.42 | 0.15 | 0.68 | 1.34 | 3.44 |
Net Debt / FCF Ratio | 0.43 | 1.45 | 0.19 | 1.24 | 2.53 | 4.21 |
Asset Turnover | 0.43 | 0.44 | 0.56 | 0.47 | 0.39 | 0.33 |
Inventory Turnover | 2.65 | 2.32 | 2.44 | 2.19 | 2.04 | 1.82 |
Quick Ratio | 1.51 | 1.44 | 1.37 | 0.85 | 1.13 | 0.66 |
Current Ratio | 2.40 | 2.41 | 2.13 | 1.56 | 1.67 | 1.25 |
Return on Equity (ROE) | 7.45% | 9.59% | 18.81% | 14.27% | 7.49% | 2.36% |
Return on Assets (ROA) | 4.54% | 5.79% | 10.49% | 7.22% | 4.22% | 2.56% |
Return on Invested Capital (ROIC) | 7.13% | 9.35% | 17.70% | 12.48% | 7.17% | 4.03% |
Return on Capital Employed (ROCE) | 8.70% | 11.20% | 20.20% | 15.60% | 8.70% | 5.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.11% | 3.40% | 5.30% | 5.04% | 2.07% | - |
FCF Yield | 4.36% | 2.00% | 6.62% | 5.07% | 3.24% | - |
Dividend Yield | 2.04% | 1.74% | 2.37% | 2.83% | 1.11% | - |
Payout Ratio | 68.30% | 80.90% | 38.92% | 30.85% | 34.71% | 150.70% |
Buyback Yield / Dilution | -2.15% | -1.76% | 0.75% | -14.28% | -5.59% | 7.21% |
Total Shareholder Return | -0.11% | -0.02% | 3.11% | -11.45% | -4.49% | 7.21% |